Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL.

Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5.

2.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113. Epub 2010 May 27.

3.

Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.

Ha JS, Jeon DS, Kim JR, Ryoo NH, Suh JS.

Ann Clin Lab Sci. 2014 Spring;44(2):173-9.

PMID:
24795056
4.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A.

Cancer Res. 2013 Feb 1;73(3):1076-85. doi: 10.1158/0008-5472.CAN-12-0735. Epub 2012 Oct 11.

5.

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.

Asian Pac J Cancer Prev. 2015;16(12):5013-8.

7.

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.

Asian Pac J Cancer Prev. 2016;17(3):923-6. Review.

8.

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.

PMID:
25082530
9.

A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.

Shen XH, Sun NN, Yin YF, Liu SF, Liu XL, Peng HL, Dai CW, Xu YX, Deng MY, Luo YY, Zheng WL, Zhang GS.

Oncotarget. 2016 Feb 23;7(8):9550-60. doi: 10.18632/oncotarget.7072.

10.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM.

Blood. 2014 Oct 16;124(16):2507-13; quiz 2615. doi: 10.1182/blood-2014-05-579136. Epub 2014 Jul 18.

11.

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM.

Blood. 2011 Nov 10;118(19):5227-34. doi: 10.1182/blood-2011-06-363424. Epub 2011 Sep 14.

12.

The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.

Chen Y, Fang F, Hu Y, Liu Q, Bu D, Tan M, Wu L, Zhu P.

PLoS One. 2016 Apr 25;11(4):e0154183. doi: 10.1371/journal.pone.0154183. eCollection 2016.

13.

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].

Liu L, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):239-43. Review. Chinese.

PMID:
21362261
14.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

15.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
16.

Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.

Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.

Blood Cells Mol Dis. 2016 Mar;57:54-7. doi: 10.1016/j.bcmd.2015.12.005. Epub 2015 Dec 10.

PMID:
26852656
17.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
18.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
19.

Myeloproliferative neoplasms: Current molecular biology and genetics.

Saeidi K.

Crit Rev Oncol Hematol. 2016 Feb;98:375-89. doi: 10.1016/j.critrevonc.2015.11.004. Epub 2015 Nov 28. Review.

PMID:
26697989
20.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S.

Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.

Supplemental Content

Support Center